Kandenko, Amano ETC (Additional) Rating

Upgraded - Bullish Code Stock Name Securities Company Previous Change After----------------------------------------------------------------- <4626> Taiyo HD Morgan S "Equal W" "Over W" <8308> Resona HD Nomura "Neutral" "Buy" Target Price Change Code Stock Name Securities Company Previous Change After-------------------------------------

Fisco Japan2minutes ago

ZETA---Kao's "My Kao Mall" introduces the review, feedback, and Q&A engine "ZETA VOICE."

On the 30th, ZETA <6031> announced that its review, feedback, and Q&A engine "ZETA VOICE" has been introduced to the official online shop "My Kao Mall" operated by Kao <4452>. With this introduction, "ZETA VOICE" is supporting the improvement of UX. The site already features the EC Commodity ETF search and site search engine "ZETA SEARCH," and a recommendation engine."

Fisco Japan16minutes ago

Stocks hitting the upper and lower limits before the market.

■ Limit up <4240> Cluster Technology <4506> Sumitomo Pharma ■ Limit down <6836> Plat Home *Includes temporary limit up and down (indicative prices).

Fisco Japan40minutes ago

SMS, ETC continue to rank, announcing Share Buyback and the introduction of progressive Dividends.

SMS <2175> has ranked in (as of 10:32 AM). It surged. After the market closes on the 28th, the financial results for the fiscal year ending March 2025 will be announced. The operating profit is 6.335 billion yen (a 23.4% decrease compared to the previous year). The previous Financial Estimates were 6.3 billion yen. The operating profit for the fiscal year ending March 2026 is estimated to be 7.287 billion yen (a 15.0% increase compared to the previous year). At the same time, a Share Buyback of up to 3.98% of the outstanding Stocks was announced. The acquisition period is from April 30, 2025, to July 31. Furthermore, the Dividends policy has been changed to adopt progressive Dividends.

Fisco Japan21:38 ET

Sumitomo Pharma --- reached the upper limit of price increase, significantly revised upwards beyond expectations, making an impact.

The stock reached its upper limit. The upward revision of the financial results for the fiscal year ending in March 2025 was announced the day before yesterday. The core operating profit was raised from the previous estimate of 30 billion yen to 43.2 billion yen, while the previous term had a loss of 133 billion yen. In the North America segment, the treatment for advanced prostate cancer "Orgovix" appears to be exceeding expectations. Although impairment losses will be recognized, the operating profit has also been raised from 21 billion yen to 28.8 billion yen, significantly exceeding the market consensus of approximately 15 billion yen.

Fisco Japan21:23 ET

Japanese Stocks Rise at Open Tracking Wall Street Momentum

MT Newswires20:50 ET